7 research outputs found
Adalimumab or Etanercept as first line biologic therapy in Enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years
Objectives: To analyse and compare drug-survival of adalimumab and etanercept (and their biosimilars) in biologic-naĂŻve patients with ERA (Enthesitis-Related Arthritis). // Methods: In this retrospective observational study, conventional statistics and machine-learning were applied to compare drug-survival (adalimumab, etanercept and their biosimilars initiated: 2009â2019) in ERA and identify determinants. The primary outcome was discontinuation of treatment due to primary- or secondary-failure and adverse drug-reactions. // Results: During the observation period, 99 of 188 patients with ERA on first-line TNF inhibitors (etanercept-n=108, adalimumab-n=80) discontinued their treatment (median survival-time 3.9years, 95%CI 2.6-4.9years). Adalimumab was associated with longer drug-survival compared to etanercept especially after an initial positive response, with the median time to treatment discontinuation 4.9years (95% CI 3.9â5.7) for adalimumab, compared to 2years (95%CI 1.4â4.0) for etanercept (HR of treatment-discontinuation-0.49, 95%CI 0.32â-0.75, p=0.001). Adjusted by propensity-score, adalimumab-methotrexate combination was associated with longer drug survival, compared to adalimumab-monotherapy (HR-0.41, 95%CI 0.20â0.85), etanercept-monotherapy (HR-0.28, 95%CI 0.15â0.53), and etanercept-methotrexate combination (HR-0.39, 95%CI 0.21â0.73). The presence of HLA-B27 was associated with longer drug-survival (HR-0.50, 95%CI 0.29â0.87) following an initial positive response. Higher-CRP at baseline was associated with higher rate of primary-failure (HR-1.68, 95%CI 1.08â2.62). Axial-ERA (sacroiliitis±spinal-involvement) was associated with poorer drug-survival for both primary- and secondary-failure (overall HR-2.03, 95%CI 1.22â3.40). Adjusted by propensity-score, shorter drug-survival was observed in patients with baseline-CRPâ„12.15 mg/L, but only in the context of axial-ERA, not in peripheral-ERA (no sacroiliitis/spinal-involvement) (HR-2.28, 95%CI 1.13â-3.64). // Conclusion: Following an initial positive primary response, continuing methotrexate with adalimumab was associated with the longest drug-survival compared to adalimumab-monotherapy or etanercept-based regimens. Axial-ERA was associated with a poorer drug-survival. A CRP >12.15 in patients with axial-ERA was associated with a higher rate of primary-failure. Further prospective studies are required to confirm these findings
Cardiovascular Disease and Cardiac Imaging in Inflammatory Arthritis
Cardiovascular morbidity and mortality are more prevalent in inflammatory arthritis (IA) compared to the general population. Recognizing the importance of addressing this issue, the European League Against Rheumatism (EULAR) published guidelines on cardiovascular disease (CVD) risk management in IA in 2016, with plans to update going forward based on the latest emerging evidence. Herein we review the latest evidence on cardiovascular disease in IA, taking a focus on rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis, reflecting on the scale of the problem and imaging modalities to identify disease. Evidence demonstrates that both traditional CVD factors and inflammation contribute to the higher CVD burden. Whereas CVD has decreased with the newer anti-rheumatic treatments currently available, CVD continues to remain an important comorbidity in IA patients calling for prompt screening and management of CVD and related risk factors. Non-invasive cardiovascular imaging has been attracting much attention in view of the possibility of detecting cardiovascular lesions in IA accurately and promptly, even at the pre-clinical stage. We reflect on imaging modalities to screen for CVD in IA and on the important role of rheumatologists and cardiologists working closely together
Cardiovascular Disease in the Systemic Vasculitides
The vasculitides are a heterogeneous group of disorders, characterized
by inflammatory cell infiltration and necrosis of blood vessels that
cause vascular obstruction or aneurysm formation, affecting various
organs such as lungs, kidneys, skin and joints. Cardiac involvement is
commonly encountered in primary systemic vasculitis and it is associated
with increased morbidity and mortality. Depending on the dominant
pathophysiological mechanism, heart complications may manifest in
different ways, including myocardial ischemia due to impaired micro- or
macrovascular circulation, progressive heart failure following valvular
heart disease and myocardial dysfunction, (sub) clinical myocarditis,
pericarditis, pulmonary hypertension as well as arteritis of coronary
vessels. Beyond cardioprotective regimens, aggressive immunosuppression
reduces the inflammatory burden and modulates the progression of
cardiovascular complications. Perioperative management of inflammation,
when surgical treatment is indicated, improves surgical success rates
and postoperative long-term prognosis. We aim to provide an overview of
the pathogenetic, diagnostic and therapeutic principles of
cardiovascular involvement disease in the various forms of systemic
vasculitis
Clinical trial eligibility of a real-world connective tissue disease cohort:Results from the LEAP cohort
IntroductionClassification criteria aim to identify a homogenous population of patients for research. We aimed to quantify how well phase-III trials in connective tissue diseases (CTDs) represent a real-world cohort.MethodsA comprehensive review of all major published phase-III trials in CTDs was performed (clinicaltrials.gov). Classification criteria utilised most commonly in clinical trials were applied to a multicentre unselected CTD cohort.ResultsThere were 42 CTD trials identified, with no trials in mixed (MCTD) or undifferentiated CTD (UCTD). The majority of trials (N = 38, 90 %) required patients to meet classification criteria for their respective disease. Eight (19.0 %) excluded patients with overlapping CTDs and a further two (4.8 %) excluded specific overlapping features, such as pulmonary arterial hypertension. One study explicitly allowed overlap syndromes. Our real-world CTD cohort included 391 patients. Patients with UCTD or MCTD (91/391, 23.3 %) would be excluded from participation in clinical trials for not having an eligible diagnosis. Of patients with primary Sjögren's syndrome (pSS), SLE, systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM), 211/300 (70.3 %) met the classification criteria for their respective diagnosis and 24/211 (11.4 %) met criteria for >1 CTD. In total, 187/391 (47.8 %) would be eligible for recruitment, based upon their physician diagnosis, and most stringent trial eligibility criteria.ConclusionIn an unselected, real-world CTD cohort, up to half of patients are ineligible for clinical trials due to not meeting classification criteria, overlapping features or a lack of trials within their primary disease. To address this inequality in access to novel therapies, clinical trial design should evolve eligibility criteria in CTDs